Indegene IPO Details, Timeline, Price, GMP, FAQs
Indegene Limited
Indegene IPO Details
IPO Open
6 May 2024
IPO Close
8 May 2024
Price Band
₹430 – ₹452
Issue Size
₹1,847.76 Cr
Listing on
BSE, NSE
Min. Lot Size
33
Face value
₹2
GMP
₹262
IPO Timeline
IPO Open
6 May 2024
IPO Close
8 May 2024
Allotment
9 May 2024
Refund initiation
10 May 2024
Demat transfer
10 May 2024
Listing
13 May 2024
Key Performance Indicators
Debt/Equity
0.3
P/E
37.78
EPS
11.96
RoNW
18.23%
PAT Margin
12.62
P/BV
7.55
About Indegene Limited
Indegene Limited, founded in 1998, is a digital-first company that provides commercialization solutions for the life sciences industry. This includes companies in biopharmaceuticals, emerging biotech firms, and medical device manufacturers.
Indegene leverages a combination of deep healthcare knowledge, purpose-built technology, and a flexible operational model to deliver a wide range of services. Their core offerings include:
- Enterprise Commercial Solutions
- Omnichannel Activation
- Enterprise Medical Solutions
- Enterprise Clinical Solutions
- Consultancy Services
About Indegene IPO
Indegene IPO is open for subscription from May 6, 2024 to May 8, 2024. The price per share is set within a range of Rs 430 to Rs 452, with a face value of Rs 2. The minimum investment amount is Rs 14,190 (for a minimum lot of 33 shares). Linkintime India Pvt Ltd is the IPO’s registrar and SBICAP Securities Ltd. as the Book Running Lead Manager (BRLM).
Issue Details:
- Type: Book Building Issue
- Issue Size: Rs 1,841.76 Crore
- Fresh Issue: Rs 760.00 Crore (1.68 crore shares)
- Offer for Sale (OFS): Rs 1,081.76 Crore (2.39 crore shares)
- Price Band: Rs 430 – Rs 452 per share
- Minimum Lot: 33 Shares
- Open Date: May 6, 2024
- Close Date: May 8, 2024
- Listing: BSE & NSE (Tentative Listing Date: May 13, 2024)
- BRLM (Book Running Lead Manager): SBICAP Securities Ltd.
- Registrar: Linkintime India Pvt Ltd
Industry Overview
Indegene operates in the life sciences industry, but with a more specific focus on the commercialization side of things. Here’s a breakdown of the industry and Indegene’s niche:
Life Sciences Industry:
- A broad industry encompassing research, development, and manufacturing of products related to living organisms.
- Includes sectors like pharmaceuticals, biotechnology, medical devices, and healthcare IT.
- Focuses on improving human health and well-being.
Indegene’s Niche: Life Sciences Commercialization
- Indegene operates within the life sciences industry, but their specific focus is on helping companies bring new drugs, devices, and diagnostics to market.
- They leverage technology and expertise to provide services such as:
- Market access strategies
- Pricing and reimbursement solutions
- Sales force effectiveness training
- Digital and traditional marketing campaigns
- Medical information and scientific communication
- Clinical trial design, execution, and data management
Essentially, Indegene acts as a bridge between life sciences companies and the market. They help companies navigate the complexities of commercialization, ensuring their products reach the right patients and healthcare professionals.
Industry Trends:
- The life sciences industry is constantly evolving, driven by factors like:
- Technological advancements (e.g., artificial intelligence, genomics)
- Growing demand for personalized medicine
- Increasing pressure on healthcare costs
- Indegene’s focus on digital solutions and data-driven strategies positions them well to capitalize on these trends.
Overall, Indegene occupies a valuable niche within the life sciences industry. Their expertise in commercialization helps bridge the gap between innovation and patient access.
Peer Analysis
There are currently no publicly listed companies in India with a business model directly comparable to Indegene.
Indegene IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50% of the Net Issue |
| Retail Shares Offered | Not less than 35% of the Net Issue |
| NII (HNI) Shares Offered | Not less than 15% of the Net Issue |
Indegene IPO Lot Size
| Application | Lots | Shares |
|---|---|---|
| Retail (Min) | 1 | 33 |
| Retail (Max) | 13 | 429 |
| S-HNI (Min) | 14 | 462 |
| S-HNI (Max) | 67 | 2,211 |
| B-HNI (Min) | 68 | 2,244 |
Financials of Indegene
| Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|
| Assets | 2,203.87 | 1,353.47 | 596.04 |
| Revenue | 2,364.10 | 1,690.50 | 996.92 |
| Profit After Tax | 266.1 | 162.82 | 149.41 |
| Net Worth | 1,063.72 | 763.9 | 324.51 |
| Reserves and Surplus | 1,019.43 | 763.55 | 324.19 |
| Total Borrowing | 394.34 | 18.24 | 24.76 |
- Revenue: Increased steadily from ₹996.92 Crore in Mar 2021 to ₹2,364.10 Crore in Mar 2023, representing a more than 137% growth.
- Profit After Tax (PAT): Followed a similar trend, rising from ₹149.41 Crore to ₹266.11 Crore, reflecting a growth of over 78%.
- Assets: Grew substantially, reaching ₹2,203.87 Crore in Mar 2023, up from ₹596.04 Crore three years prior. This indicates potential expansion and investment in the company.
- Net Worth: Increased steadily, demonstrating a growing financial base.
- Reserves and Surplus: Showed a similar upward trend, suggesting retained earnings are being reinvested in the company.
- Total Borrowing: While the data shows some debt, the figures haven’t grown significantly over the period, indicating responsible borrowing practices.
Objective of Indegene IPO
Here are the objectives of the Indegene IPO:
- Repayment/prepayment of debt: This could involve using the capital raised to pay off existing loans or reduce their reliance on debt financing.
- Funding capital expenditure requirements: The IPO proceeds could be used to invest in infrastructure, technology, or other assets necessary for future growth.
- Acquisition of additional shares in a subsidiary: This might involve using the funds to increase their ownership stake in a strategic subsidiary.
- General corporate purposes and inorganic growth: The company might utilize the capital for various business needs, potentially including acquisitions or strategic partnerships.
FAQ about Indegene IPO
The Indegene IPO price band is set between ₹430 and ₹452 per share.
As of May 6, 2024, the Indegene IPO shares are trading at a premium of ₹262 in the grey market. It’s important to note that the grey market is unofficial and doesn’t reflect the actual listing price.
Indegene IPO listing date is May 13, 2024, on both BSE and NSE.
The minimum lot size for retail investors is 33 shares.
The subscription period for the Indegene IPO is open from May 6, 2024 (today) to May 8, 2024.
The allotment of shares for the Indegene IPO is expected to be finalized on Thursday, May 9, 2024.
Some of the objectives of the Indegene IPO include repaying debt, funding future growth, acquiring additional shares in a subsidiary, and general corporate purposes.
Indegene has shown impressive growth in recent years, with strong revenue, profit, and net worth. However, conducting your own financial analysis or consulting a financial advisor is recommended before making any investment decisions.
There is currently no public record of any major legal issues with Indegene Limited. However, due diligence is important before making any investment decisions.
Indegene operates in the life sciences industry, with a specific focus on the commercialization side of things. They help companies bring new drugs, devices, and diagnostics to market.
There are currently no publicly listed companies in India with a business model directly comparable to Indegene.
Some potential risks include the lack of directly comparable peers, the company’s limited operating history as a public company, and the overall market conditions.
Indegene IPO Subscription Status
| Category | Subscription Times |
|---|---|
| Qualified Institutional Buyers | 0.05x |
| Retail Individual Investor | 1.50x |
| Non-Instituional Investor | 4.14x |
| Employees | 1.31x |
| Total | 1.67x |
